-75%

est. 2Y upside i

HealthcareSeries A

Rank

#2637

Sector

Healthtech

Est. Liquidity

~5Y

Data Quality

Data: Low

SiteRx operates in a growing healthtech sector with a solid $24.9M in revenue and a moderate competitive moat.

Last updated: March 10, 2026

Bull (15%)+300%

SiteRx's InclusionAI platform achieves significant market penetration by securing major partnerships with large pharmaceutical companies and CROs, leveraging its unique focus on diversity in clinical trials. Revenue accelerates to $100M+ within two years, justifying a $700M valuation at a 7x multiple as it becomes a leader in AI-driven patient matching.

Base (35%)+75%

SiteRx continues steady growth, expanding its customer base among mid-sized research organizations and clinics. While facing competition from incumbents, its specialized platform maintains a niche. Revenue grows to $45M-$50M within two years, leading to a valuation of approximately $300M.

Bear (50%)-75%

Dominant incumbents like Medidata or Veeva Systems expand their AI-driven patient matching capabilities, commoditizing SiteRx's core offering. Slower-than-expected customer acquisition and increased regulatory hurdles lead to a down round or acquisition at a significantly reduced valuation of $40M-$50M, severely impacting common stock value.

Est. time to liquidity~5.0 years

Preference Stack Risk

low

Investors hold $6.2M in liquidation preferences. At an estimated current valuation of $175M, this represents a low preference stack.

Dilution Risk

moderate

As a Series A company with $6.2M in total funding, SiteRx will likely require additional funding rounds (Series B, C) in the coming years, leading to future dilution for common shareholders.

Secondary Liquidity

none

Given its early stage (Series A) and total funding, there is currently no active secondary market or tender offers for SiteRx equity.

Other — 2 roles

View all 2 open roles at SiteRx →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on SiteRx's data — designed to show you've done your homework.

  • 1

    “Given the strong presence of incumbents like Medidata and Veeva in the clinical trial software space, how does SiteRx plan to differentiate its offering and defend its market share over the next 2-3 years, especially as these larger players expand their AI capabilities?”

  • 2

    “With $24.9M in revenue and a Series A funding round in 2022, what is the company's strategy for its next funding round, and how do you envision the path to profitability or a significant liquidity event within the next 3-5 years?”

  • 3

    “The company's mission emphasizes diversity and inclusion in clinical research. How is SiteRx measuring the impact of its InclusionAI platform, and what are the key metrics for success beyond just patient enrollment numbers?”

Community

Valuation Sentiment

Our model estimates -75% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.